Ventures

UltraTIL enables real-time tool-in-lesion confirmation during endobronchial lung cancer biopsies. This compact, side-viewing ultrasound probe is designed for the peripheral airways. UltraTil can be inserted through the working channel of a bronchoscope or robotic platform. By visualising lesions perpendicular to the airway and displaying the needle or biopsy instrument entering the target, UltraTIL improves the identification and sampling of small, eccentric and hard-to-reach lesions. The result: higher diagnostic accuracy, less reliance on additional positioning instruments, and shorter, more efficient procedures.

Revadix is a pioneering biotech venture focused on transforming the treatment of atrial fibrillation (AF), a common heart rhythm disorder. The company is developing AM-001, a novel therapy that targets the EPAC-1 protein, aiming to restore normal heart rhythm and offer a curative solution rather than just symptom management. Revadix’s approach promises to improve patient outcomes with fewer side effects and better long-term health results. Supported by NLC Health Ventures, the company is advancing AM-001 towards clinical trials, with the potential to revolutionize cardiovascular care.

Ansana offers a smart sterilization container for surgical instruments, designed to tackle key challenges in the healthcare sector. By integrating electronic sensors, it ensures sterility in operating rooms, reducing the risk of infections by 10% and lowering the environmental impact of sterilization processes by 85%. Ansana's enhances patient safety with real-time monitoring and traceability features, with complex instruments like endoscopes, while also cutting costs for healthcare facilities in terms of labor and materials.

Audaxis Medical revolutionizes the treatment of stress urinary incontinence with Plielle™, a next-generation polyurethane support system. While traditional polypropylene slings often lead to chronic inflammation and tissue complications, Plielle™ offers a safer alternative by replicating the native structure and viscoelastic properties of the pelvic floor. By providing a high-performance, biocompatible solution that integrates seamlessly with human tissue, Audaxis aims to improve clinical outcomes and restore patient confidence, filling a critical gap in women’s healthcare.

Neurolieve Biosciences, a pre-clinical stage company, is developing Fc2-13 GalR2, an innovative bioengineered protein (FC fusion protein) targeting neuropathic pain. Peripheral Neuropathy, a debilitating condition affecting millions, damages the peripheral nervous system, causing severe discomfort and lowering quality of life. The fusion protein reduces peripheral neuron excitability, providing pain relief. After successful in vitro and in vivo validations, the company is advancing towards GLP toxicology studies completion.

NC Biomatrix offers a solution for treating chronic back pain caused by intervertebral disc degeneration. Current treatments only address symptoms, have limited effectiveness and often come with complications. NC Biomatrix introduces a new approach using a bio-inductive protein extract obtained from porcine notochordal biomatrix. This injectable treatment addresses the underlying pathology and aims to restore the degenerated disc as a way to definitively treat chronic back pain.

MindAffect is redefining what’s possible in diagnostics. By harnessing Brain-Computer Interface technology and AI, we can “read” how the brain reacts to sound and visual stimuli—objectively, in real time, and without requiring a single response from the patient. At the core is our patented and clinically validated Rapid CAEP® technology, which captures the brain’s automatic reactions. This breakthrough allows clinicians to diagnose patients who would otherwise be difficult or impossible to test—such as infants, seniors, and individuals with disabilities. In a world where over two billion people are underserved by current diagnostic methods, this changes everything. Our first product, Sofi, is the world’s fastest objective hearing diagnostic system, delivering accurate hearing thresholds in minutes. Sofi has been validated in leading hospitals, championed by key opinion leaders across the audiology community, and recognized globally—winning the Innovation Award at the World Congress of Audiology

The challenge with lung cancer lies in its late detection, often leading to unfortunate outcomes. Current screening methods like low-dose CT scans are costly and have radiation risks, while blood tests lack accuracy or are too expensive. Our solution offers a non-invasive blood test that detects lung cancer early with high sensitivity and specificity. This test, with its multi-protein panel, can identify even stage I cancer, improving survival rates and reducing unnecessary procedures.